ArticleReports of biochemistry & molecular biology2025
Effect of Zinc Oxide Nanoparticles on Hepatic Ischemia-Reperfusion Injury: Role of miR-125b Expression in Possible Underlying Mechanisms.
Article in Reports of biochemistry & molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study examined the protective effects of zinc oxide nanoparticles (ZnO-NPs) on hepatic ischemia-reperfusion injury (HIRI) and their possible underlying mechanisms. Methods: 48 male rats were randomly divided into six groups (n=8): the sham group that received intraperitoneal normal saline solution (Sham), the HIRI group, the control groups pre-treated with 5 and 10 mg/kg ZnO-NPs for 3 consecutive days without surgery (ZnO5) and (ZnO10), the HIRI group pre-treated with 5 mg/kg ZnO-NPs for 3 consecutive days before surgery (HIRI+ZnO5), and the HIRI group pre-treated with 10 mg/kg ZnO-NPs for 3 consecutive days before surgery (HIRI+ZnO10). One hour after reperfusion, serum and tissue samples were collected for biochemical, molecular and histopathological evaluation. Results: Administration of ZnO-NPs caused significant improvement in the elevated serum concentrations of ALT, AST, TOS and MDA, improved liver histopathology, and increased TNF-α, IL-6, and NF-κB levels in liver tissue compared to HIRI group. In addition, administration of ZnO-NPs increased the expression of miR-125 in liver tissue compared than in the HIRI group. Conclusions: The administration of ZnO-NPs improved the effect on HIRI by enhancing miR-125b expression and suppressing oxidative stress and inflammatory cytokines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.